Clinical trials: Percutaneous Coronary Intervention Patients
Healthy, Nurse's Role
Music Application in Patients Undergoing Percutaneous Coronary Intervention
This study was planned to examine the effect of music application on recovery in patients undergoing coronary angiography (CAG) and to obtain the opinions of patients and nurses about music.This study was conducted to examine the…
- Conditions
- Healthy, Nurse's Role, Patient Satisfaction
- Trial name
- NCT06293248
- Testing
- musical application
- Where
- Turkey (Türkiye)
- Volunteers
- 210 people
- Sponsor
- Kocaeli University
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Hungary Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES)
- Trial name
- NCT01892917
- Where
- 13 sites in Hungary
- Volunteers
- 2,000 people
- Sponsor
- Biotronik Hungária Kft.
STEMI, Primary PCI
Early Administration of Heparin At FMC for PPCI of STEMI Patients
Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients. However, the priority of use of hepairn in first medical contact or in Cathlab has not yet studied.
- Trial name
- HELP-PCI (NCT05329155)
- Testing
- Heparin Sodium Injection
- Where
- China
- Volunteers
- 1,145 people
- Sponsor
- Renmin Hospital of Wuhan University
Atrial Fibrillation, Antithrombotic Therapy
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
More than 25% of patients referred for diagnostic coronary angiography and percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS) suffer from non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome, Percutaneous Coronary Interventions
- Trial name
- ADONIS-PCI (NCT04695106)
- Testing
- Ticagrelor, Dabigatran Etexilate, Aspirin
- Where
- Poland
- Volunteers
- 1,194 people
- Sponsor
- Medical University of Gdansk
High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary
VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)
The VITALYST Early Feasibility study (EFS) is designed to evaluate the feasibility and safety of the VITALYST System in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
- Trial name
- VITALYST EFS (NCT06132568)
- Testing
- VITALYST System
- Where
- 5 sites in United States, Sweden
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Myocardial Ischemia, Ischemic Reperfusion Injury
Remote Ischemic Preconditioning in Elective Percutaneous Interventions
Myocardial injury occurs after percutaneous coronary intervention due to micro emboli, ischemia-reperfusion injury or side branch occlusion.
- Trial name
- NCT02581618
- Testing
- remote ischemic preconditioning
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Trakya University
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE China Registry:
To document the safety and overall clinical performance of the Resolute Zotarolimus-Eluting Coronary Stent System in a real-world patient population requiring stent implantation.
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- R-C Registry (NCT01243749)
- Where
- 6 sites in China
- Volunteers
- 1,800 people
- Sponsor
- Medtronic Vascular
Acute ST Segment Elevation Myocardial Infarction
Retrospective Evaluation of SuperSaturated Oxygen (SSO2) Therapy Clinical Utility
The purpose of this multicenter study is to assess the impact of SSO2 treatment on clinical outcomes and left ventricular function in patients following acute ST-segment elevation myocardial infarction (STEMI).
- Trial name
- RESCU (NCT05949515)
- Where
- 8 sites in United States
- Volunteers
- 403 people
- Sponsor
- Cardiovascular Research Foundation, New York
Acute Coronary Syndrome, Acute Myocardial Infarction
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- STOPDAPT-2 ACS (NCT03462498)
- Testing
- 1-months DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,008 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Chronic Total Occlusion Vessel
Benefits of CTO-PCI in Selected Cases With HFrEF (CTOHFrEF)
The investigators studied the effect of CTO-PCI on left ventricular function and clinical parameters in patients with HFrEF.
- Trial name
- CTOHFrEF (NCT02570087)
- Testing
- chronic total coronary occlusion percutaneous intervention
- Volunteers
- 39 people
- Sponsor
- Hospital Clinic of Barcelona
AKI - Acute Kidney Injury
Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients
Contrast-associated acute kidney injury (CA-AKI) is a common complication of procedures with intravascular contrast. Generally, CA-AKI is defined as serum creatinine (Scr) ≥ 25 to 50% or Scr rise around 0.3 to 0.5 mg/dl.
- Trial name
- NCT05540184
- Testing
- Trimetazidine 35 mg, Allopurinol 300 MG, Normal saline
- Where
- Egypt
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Beni-Suef University
Myocardial Infarction
Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI
The purpose of this study is to demonstrate the benefit of bivalirudin in combination with clopidogrel with provisional GPIIb/IIIa inhibitor use, in reducing the bleeding complications associated with early invasive management of…
- Trial name
- NCT00093184
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- The Medicines Company
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW III Asia Registry Orsiro Stent System
Cliflical evaluation of th' Orsiro LESS 10 diabetic subjects requiring coronary revasculariza t ion with Drug Eluting Stefl ts (DES) .880 subjects will be enrolled in this registry.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01941290
- Where
- 19 sites in China, India and 3 more
- Volunteers
- 387 people
- Sponsor
- BIOTRONIK Asia Pacific Pte Ltd
Acute Coronary Syndrome
Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Everolimus-eluting Stents
The SORT OUT XII dual antiplatelet treatment (DAPT) duration trial, is a clinical randomized controlled superiority and non-inferiority trial to compare whether prasugrel alone versus prasugrel plus aspirin from month 1 to month…
- Trial name
- SORT OUT DAPT (NCT06718179)
- Testing
- Short duration of aspirin and prasugrel, Conventional duration of aspirin and prasugrel
- Where
- 3 sites in Denmark
- Volunteers
- 130 people
- Sponsor
- Odense University Hospital
ST Segment Elevated Myocardial Infarction
Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With STEMI
The study intends to evaluate the efficacy of early rhBNP on myocardial remodeling and reperfusion in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention
- Trial name
- NCT04033861
- Testing
- rhBNP, Control
- Where
- China
- Volunteers
- 352 people
- Sponsor
- RenJi Hospital
Coronary Heart Disease, Myocardial Injury
Intranasal Dexmedetomidine and Perioperative Myocardial Injury
PCI is the standard treatment for CAD, yet perioperative myocardial injury occurs frequently in nearly 40% of patients. Perioperative stress and sympathetic overactivation break myocardial oxygen balance and lead to cardiac…
- Conditions
- Coronary Heart Disease, Myocardial Injury, Myocardial Infarction, Dexmedetomidine
- Trial name
- NCT07549282
- Testing
- Intranasal Dexmedetomidine, Normal saline
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Comorbidities and Coexisting Conditions, Ethics
eCardiacRehab - a Hybrid Patient-Centered eHealth Programme
The overall aim of eCardiacRehab trial is to meet rehabilitation needs of patients with coronary artery disease (CAD) regardless of their access to traditional place-based rehabilitation by developing and evaluating the efficacy…
- Conditions
- Comorbidities and Coexisting Conditions, Ethics, Continuity of Patient Care, Older Adults (65 Years and Older)
- Trial name
- eCardiacRehab (NCT07590635)
- Testing
- eCardiacRehab
- Where
- Norway
- Volunteers
- 1,000 people
- Sponsor
- Haukeland University Hospital
Myocardial Infarction
Relationship Between Primary Percutaneous Coronary Intervention, Door-to-balloon Times, and Mortality for Heart Attack Patients Across England
The degree to which elevated mortality associated with weekend or night-time hospital admissions reflects poorer quality of care ('off-hours effect') is a contentious issue.
- Trial name
- NCT02374190
- Testing
- Standard Hospital Care
- Where
- United Kingdom
- Volunteers
- 42,677 people
- Sponsor
- London School of Economics and Political Science
Myocardial Infarction, Acute Coronary Syndromes
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is…
- Conditions
- Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
- Trial name
- SAVI-PCI (NCT01522417)
- Testing
- Short Tirofiban, Eptifibatide, Long Tirofiban
- Where
- 13 sites in United States
- Volunteers
- 535 people
- Sponsor
- Medicure
Ischemic Heart Disease, Atrial Fibrillation
Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients
Preliminary experiences suggest that intermittent anticoagulation guided by continuous electrocardiographic monitoring can reduce the incidence of bleeding in patients with episodes of atrial fibrillation.
- Trial name
- INTERMITTENT (NCT04151680)
- Testing
- Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban, Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza